



Pluripotent stem cells to model and treat lung disease



Darrell N. Kotton, M.D.
Center for Regenerative Medicine
of Boston University and Boston
Medical Center (CRoM)

Wednesday, Oct. 30
Noon

Duncan Building, Floor 8, Elevator Q
Conference Rooms 5 and 6 (CPB8.3402)



Accreditation/Credit Designation:

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience and Educational Objectives:

After attending this activity, the target audience of Physicians, Advanced Practice Providers, Pharmacists should be able to:

- Determine indications for SCT (Competence, Performance, Patient Outcomes);
- Treat Graft vs Host Disease (Knowledge, Competence, Performance, Patient Outcomes);
- Diagnose and treat Graft failure (Knowledge, Competence, Performance, Patient Outcomes);
- Understand treatment guidelines for prevention of infection post HCT (Knowledge);
- Discuss advancements in SCT and tissue engineering technologies in regenerative medicine (Knowledge, Competence, Performance, Patient Outcomes).

It is the policy of The University of Texas MD Anderson Cancer Center that the program chair(s), planning committee member, faculty/teacher/ author, or CME activity reviewer must disclose any relevant financial relationships with commercial interests whose products may be discussed in the activities, if any. MD Anderson also requires that faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

THE UNIVERSITY OF TEXAS
MD Anderson
Cancer Center

Making Cancer History®